Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers
Prevalence of sexually transmitted infections and associated risk factors among populations of drug abusers
复制标题
DOI：
10.1086/318131
复制
发表时间：
2000-10-01
影响因子：
11.8
通讯作者：
Holleman, M
中科院分区：
文献类型：
--
作者：
Hwang, LY;Ross, MW;Holleman, M
1998年对407名戒毒所吸毒者进行了性传播疾病和危险行为的横断面调查。通过检测血清抗体水平检测人类免疫缺陷病毒（HIV）、B肝炎病毒（HBV）、丙型肝炎病毒（HCV）、单纯疱疹病毒2型（HSV-2）和梅毒感染;通过检测尿液核酸水平检测衣原体和淋病。进行Logistic回归分析以衡量相关性。抗体流行率如下：HSV-2，44.4%; HCV，35.1%; HBV，29.5%; HIV，2.7%。梅毒患病率为3.4%，衣原体患病率为3.7%，淋病患病率为1.7%。在407名受试者中，62%的受试者有1种性病的标志物。HIV感染与非裔美国人种族、吸食可卡因和性病史有关。HBV感染与年龄>30岁、注射毒品、共用针头、药物滥用治疗史和非裔美国人种族有关。HCV感染与年龄>30岁、注射毒品和共用针头有关，HSV-2感染与年龄>30岁、女性和非裔美国人有关。梅毒与性病史有关。吸毒者中性病的高发率表明，有必要将性病筛查和治疗纳入戒毒方案。
A cross-sectional survey was conducted of sexually transmitted diseases (STDs) and risky behaviors among 407 drug abusers in treatment facilities in 1998. Infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus type 2 (HSV-2), and syphilis were detected by testing serum antibody levels; chlamydia and gonorrhea were detected by testing nucleic acid levels in urine. Logistic regression analysis was performed to measure associations. Prevalences of antibodies were as follows: to HSV-2, 44.4%; to HCV, 35.1%; to HBV, 29.5%; to HIV, 2.7%. The prevalence of syphilis was 3.4%; of chlamydia, 3.7% ; and of gonorrhea, 1.7%. Of the 407 subjects, similar to 62% had markers for 1 of the STDs. HIV infection was associated with African American race, use of smokable freebase (crack) cocaine, and STD history. HBV infection was associated with age >30 years, injecting drugs, needle sharing, a history of treatment for drug abuse, and African American race. HCV infection was associated with an age >30 years, injecting drugs, and needle sharing, and HSV-2 infection with an age >30 years, female sex, and African American race. Syphilis was associated with a history of STDs. High prevalences of STDs among drug abusers indicate the need for integration of STD screening and treatment into drug treatment programs.